TOP TEN perturbations for 1040_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1040_s_at
Selected probe(set): 225098_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1040_s_at (225098_at) across 6673 perturbations tested by GENEVESTIGATOR:

ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):-3.0289955
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).

ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)

Relative Expression (log2-ratio):3.0120287
Number of Samples:13 / 2
Experimental ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted).

T-cell activation study 1 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):-2.6792278
Number of Samples:2 / 2
Experimental T-cell activation study 1
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 1 day.
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

glioma study 16 (LN-215) / normal astrocyte sample

Relative Expression (log2-ratio):-2.6184263
Number of Samples:2 / 3
Experimental glioma study 16 (LN-215)
Human glioma cell line LN215 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

precursor-B-ALL study 3 (BCR-ABL) / T-ALL study 3

Relative Expression (log2-ratio):-2.5859823
Number of Samples:4 / 29
Experimental precursor-B-ALL study 3 (BCR-ABL)
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(9;22)(q34;q11.2)/BCR-ABL1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).
Control T-ALL study 3
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO).

T-ALL study 1 / normal bone marrow sample

Relative Expression (log2-ratio):2.565342
Number of Samples:174 / 74
Experimental T-ALL study 1
Bone marrow samples of patients with T-ALL.
Control normal bone marrow sample
Non-leukemic and healthy bone marrow sample.

zalypsis study 2 / untreated OPM1 cell sample

Relative Expression (log2-ratio):-2.562418
Number of Samples:2 / 2
Experimental zalypsis study 2
OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:---
Control untreated OPM1 cell sample
OPM1 multiple myeloma cells untreated.

tunicamycin study 2 (2ug/ml; HCT 116) / untreated HCT 116 cell sample

Relative Expression (log2-ratio):2.4425783
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; HCT 116)
Human colon carcinoma cell line HCT116 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 cell sample
Human colon carcinoma cell line HCT116 was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

Merkel cell carcinoma study 3 (primary) / skin squamous cell carcinoma study 6

Relative Expression (log2-ratio):2.3882656
Number of Samples:19 / 4
Experimental Merkel cell carcinoma study 3 (primary)
Primary tumor tissue from the skin of patients with Merkel cell carcinoma.
Control skin squamous cell carcinoma study 6
Primary tumor tissue from the skin of patients with squamous cell carcinoma (SCC).

colorectal cancer study 4 (recurring) / adjacent colon tissue (recurring)

Relative Expression (log2-ratio):2.3690128
Number of Samples:24 / 3
Experimental colorectal cancer study 4 (recurring)
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients developed metastatic recurrence during follow-up after surgery.
Control adjacent colon tissue (recurring)
Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). With metastatic recurrence after resection during follow-up.